Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Intrinsic Value: Projected FCF is $-5.73 as of Aug. 16, 2026. GuruFocus rates MLLCF with a GF Score™ of 34/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 259 Biotechnology companies, Molecular Partners AG ranks worse than 386100% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Molecular Partners AG's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Molecular Partners AG was 10.35. The lowest was 0.93. And the median was 1.21.
MLLCF's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.21 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Molecular Partners AG (OTCPK:MLLCF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Molecular Partners AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
3.80
/
-5.7903597619275
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Intrinsic Value: Projected FCF Related Terms
Molecular Partners AG Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Intrinsic Value: Projected FCF Chart
MLLCF vs VRTX, REGN, RVMD: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, Molecular Partners AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Price-to-Projected-FCF falls into.
Molecular Partners AG Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $-5.73 mean?
Molecular Partners AG (MLLCF) has a Intrinsic Value: Projected FCF of $-5.73 as of Aug. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Molecular Partners AG and its competitors. Over the past decade, Molecular Partners AG's Intrinsic Value: Projected FCF has ranged from 0.93 to 10.35. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 259 companies in the Biotechnology industry.
Is Molecular Partners AG's Intrinsic Value: Projected FCF too high?
Molecular Partners AG's current Intrinsic Value: Projected FCF is $-5.73. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 10.35. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 259 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 259 companies for Intrinsic Value: Projected FCF. This places Molecular Partners AG in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 2.21. Historically, Molecular Partners AG's own Intrinsic Value: Projected FCF has ranged from 0.93 to 10.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.21, based on 259 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Intrinsic Value: Projected FCF is $-5.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.80 — trading 645.1% above its estimated fair value. The current Intrinsic Value: Projected FCF is $-5.73. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Intrinsic Value: Projected FCF is $-5.73 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 645.1% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Intrinsic Value: Projected FCF: $-5.73
GF Value™: $0.51 vs. price of $3.80 (645.1% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
